We have identi®ed a region of chromosome 1p31.1 that shows high frequency loss of heterozygosity (LOH) in human breast cancer. This region forms part of a 7 Mb YAC/BAC contig. In order to identify candidate sequences, mutation of which might contribute to the development of disease, we have carried out mapping studies of ESTs localized to 1p31.1. This analysis, coupled with library screening and a modi®ed 5' RACE-PCR strategy, resulted in the identi®cation and characterization of a novel gene (LPHH1) which is located adjacent to the smallest region of overlapping loss (SRO) seen in tumours. The 4209 bp open reading frame of the 7 kb LPHH1 transcript encodes a peptide which shows approximately 65% identity to rat latrophilin, a Gcoupled, seven span transmembrane protein, which binds a-latrotoxin. In the human sequence, whilst conservation of the transmembrane domain is high, the intra-and extracellular domains show two regions of variable structure, which are presumably generated by alternative splicing. Surprisingly, while expression of the rat gene is tightly restricted to neurological and perhaps some endocrine cells, the human sequence appears to be expressed very widely in all normal tissues tested. Northern and RT-PCR analysis of a panel of tumour cell lines showed that LPHH1 expression was variable, apparently elevated in some lines and absent or markedly reduced in others. Furthermore, characterization of the range of transcripts encoded in a breast tumour cell line, compared to normal breast, suggested that gene product variability was higher in the tumour.
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In malignant disease, loss of heterozygosity of multiple chromosomal regions occurs with variable frequency in many dierent tissues. It is thought that such events reveal the location of genes, mutated versions of which contribute to the malignant phenotype. However, LOH patterns in tumours are often highly complex and suggestive of multiple suppressors within a given chromosome arm or sub-region. In an attempt to utilize such data, the simplest hypothesis, that overlapping regions of loss indicate the location of a single suppressor, is generally the ®rst to be tested. In a study of breast tumour samples, we have previously reported the identi®cation of one such region of high frequency loss (60%) on chromosome 1 within band 1p31.1 (Hoggard et al., 1995a) . Analysis of individual lesions, at high resolution, with multiple microsatellite markers, permitted the de®nition of a small region of overlapping loss (Hoggard et al., 1995b) . This same putative LOH target was also identi®ed in a second independent breast cancer study (Nagai et al., 1995) . Our primary hypothesis was that the region contained, at least in part, a sequence linked to the development of breast cancer. However, we were aware of alternative possibilities. In particular, we felt that it was conceivable that loss events might aect the expression of genes located in the vicinity of but not necessarily within the SRO, perhaps as a consequence of the deletion of cis regulatory elements. We were also aware that in de®ning our hypothesis we were assuming only one regional LOH target. If the number of potential targets were to be more than one, then the area to be screened for candidate genes would widen considerably. It was to prepare to address these possibilities that the wider 7 Mb 1p31.1 YAC contig was constructed (Hoggard et al., 1995b) .
In an attempt to localize candidate genes implicated in maintenance of the malignant phenotype, screening of ESTs against the YAC clones in the 1p31.1 contig was carried out. A number of ESTs were identi®ed through the Human Gene Map as being encoded from within the interval de®ned by D1S216 and D1S207, markers which¯anked the 1p31.1 YAC contig and SRO. PCR analysis of these sequences revealed that while none were encoded from within the SRO, two (WI-11936, P38/P39 and A009A09, P35/P36) mapped to YAC clone 20AD1 but not to 37EC1 or 3ED6 (Hoggard et al., 1995b) . In addition to the YAC mapping data, subsequent screening of a BAC library for these two ESTs led to the identi®cation of a clone (61G4) encoding both sequences. The 1p31.1 marker AFM356tb9 colocalized to both 20AD1 and 61G4 con®rming the genomic position. These data placed the ESTs approximately 1 Mb (4 cM) centromeric to the SRO. Subsequent sequencing demonstrated that they were both derived from the same transcript. Use of one primer from each (P35, P39) allowed the ampli®cation of a 750 bp region of continuous genomic sequence that was used as a hybridization probe in Northern analysis to investigate the normal human tissue expression pattern. A double signal, of variable relative intensity, of 6 ± 7.5 kb was seen in all tissues (mRNA loading normalized with b-actin) with highest levels of expression seen in heart, placenta and lung, moderate levels in brain, liver, kidney and pancreas and a low level in skeletal muscle (Figure 1 ).
cDNA isolation
Based on the expression data suggesting a wide expression pro®le and given our interest in breast cancer, cDNA libraries derived from normal brain (Stratagene 936205) skeletal muscle, and a breast carcinoma cell line (Clontech HL5002a and HL1059a) were screened by hybridization, initially with the EST derived fragment and subsequently with more 5' cDNA sequence. A number of clones (31) were picked and analysed. The human cDNA sequence identi®ed was highly homologous to the 3' end of the previously described rat latrophilin gene (LPH1). The novel gene was designated as LPHH1 (latrophilin homologue 1). Rat latrophilin or CIRL (calcium-independent receptor of a-latrotoxin) is a recently cloned 7TM G-coupled protein, a member of the secretin receptor family (Krasnoperov et al., 1997; Lelianova et al., 1997) . Although the natural ligand and therefore normal cellular function are unknown, latrophilin interacts with a-latrotoxin, a potent neurotoxin derived from black widow spider venom. This action is independent of calcium ions and brings about massive neurotransmitter release (Geppert et al., 1998) . LPH1 was initially thought to be expressed exclusively in rat neural tissue (especially the cerebral cortex) and the transcript was not detected in liver, kidney, lung, heart, muscle and spleen (Davletov et al., 1996 and Krasnoperov et al., 1996) . More recently it has been shown to be expressed in primary and established cell lines of rodent pancreatic b-cells suggesting a possible additional role for the protein in endocrine secretion (Lang et al., 1998) . It appears that latrophilin may normally act by inhibiting the secretory pathway, a process blocked by binding the a-latrotoxin ligand (Bittner et al., 1998) .
Based on the expected homology with the rat LPH1 open reading frame, we hypothesized that our longest human clone was likely to be under fulllength by approximately 1.5 kb. Despite extensive library screening with 5' probes we were unable to identify any further latrophilin clones containing this region. In order to test our hypothesis, SMART TM PCR cDNA libraries were constructed from mRNA derived from normal breast tissue and MDA231. The SMART TM system (Clontech) was used as it is aimed speci®cally at the production of libraries containing cDNAs with extended 5' regions. To increase the speci®city of our 5' RACE reaction, a modi®cation of the basic protocol was used. Following ®rst strand cDNA synthesis, an internal latrophilin primer (P18) and the 5' cap speci®c primer were used to drive the PCR cDNA library ampli®cation (Advantage cDNA PCR Kit, Clontech). (Clontech) shows expression of the gene in all samples. The ®lter was pre-hybridized (2 h) and hybridized (1 h) with a random prime, 32 P-labelled (Random Primed DNA Labelling Kit, Boehringer) PCR generated probe (3' region of cDNA, P35/39) in 10 ml of ExpressHyb Hybridization solution (Clontech). PCR products were cleaned prior to labelling using a Wizard PCR Preps DNA Puri®cation System (Promega). Following hybridization, the ®lter was washed in 4 changes of 26SSC at 658C. The subsequent hybridization signal appears to be at least double. Given our data and whilst not ruling out other explanations, such as variable initiation and polyadenylation sites, we feel that this eect is most likely to be a consequence of alternative splicing. Tracks are (a) heart (b) brain (c) placenta (d) lung (e) liver (f) skeletal muscle (g) kidney (h) pancreas. (B) The agarose gels show RT-PCR analysis of expression in mRNA derived from normal and breast and a panel of tumour cell lines, showing alternative products from the 5' (panel 1) and 3' (panel 2) variable domains. Extraction of mRNA from cell pellets (1610 7 ) was carried out using an Invitrogen Fast Track TM 2.0 mRNA isolation system. The cDNA target was generated by reverse transcription of 1 mg of mRNA in a 40 ml reaction using a Reverse Transcription System (Promega). For each RT-PCR assay 1 ml of this ®rst strand synthesis was ampli®ed over 30 cycles in a standard 100 ml reaction. The ®rst two tracks (a, b) are nested RT-PCR products of full length cDNA ampli®cations whilst c ± j are primary RT-PCRs of ®rst strand cDNA synthesis reactions using the same internal primers, which¯ank the variable domains. Tracks are a, normal breast (Clontech) b, MDA231 (ATCC HTB 26) c, normal breast d, MDA231 e, CALU1 (ATCC HTB 54) f, A549 (ATCC CCL 185) g, KARPAS-620 (Nacheva et al., 1990) h, SK-UT-1B (ATCC HTB 115) i, SK-N-SH (ATCC HTB 11) j, A2780 (Eva et al., 1982) k, control ampli®cation (no target). Flanking markers are FX174/HaeIII digests. No product was detected from KARPAS-620 at either site. The primers used (1: P17/P22 and 2: P34/P31) are speci®c for cDNA (intron spanning) Figure 2 The sequence of the most abundant LPHH1 cDNA clone in normal breast (AV) is detailed. Sequencing was carried out on an ABI 377 system using a Big Dye DNA Sequencing Kit (ABI). For analysis of the LPHH1 coding region, the full open reading frame was ampli®ed (Expand TM Long Template PCR System, Boehringer) initially using primers (P1/P39) sited in the determined 5' and 3' untranslated regions of the gene. The *5 kb products were thereafter used as templates for internal, overlapping, nested PCR reactions which formed the templates for sequence determination. Reaction products were cleaned prior to sequencing using a Wizard PCR Preps DNA Puri®cation System (Promega). The majority of the coding sequence, with the exclusion of the variable domains, was determined in both directions, in a direct analysis, from both cDNA sources, using in various combinations, primers P2 to P37 (Table 1) . Analysis of ®nished sequence and database searching were carried out using GCG Wisconsin Sequence Analysis software programmes. Predictions of transmembrane regions and orientations were made using TopPred 2 and TMpred. Scanning for consensus sequences was carried out using PSORT II and PSITE VI and PEST®nd. The translation shows the product of the long open reading frame. The predicted transmembrane regions are underlined. The putative signal peptide is highlighted by the broken line and suggested cleavage point marked by the arrow. N-glycosylation sites are marked with a *. The suggested PEST domain is identi®ed with a dotted line Subsequently, 0.5 mg of the cDNA product was ligated at 378C for 2 h with 1.5 pM of blunt end vectorette unit (Genosys) in a 30 ml reaction containing 5 units of T4 DNA ligase (Promega). This reaction was diluted to 200 ml and 1 ml used in subsequent PCR ampli®cations. The advantage of this procedural modi®cation was that subsequent ampli®cation steps become highly speci®c, as in order for the vectorette sequence to act at a 5' primer it must ®rst be copied, following a gene speci®c, internal priming/extension event. To isolate the 5' end of the latrophilin cDNA, the RACE reaction was driven with a vectorette speci®c primer (VECI, Genosys) and a gene speci®c primer (P16). A clear transcript start approximately 2 kb upstream of our internal primer was derived from the MDA231 analysis. This product was isolated from a low melt agarose gel and re-ampli®ed prior to cloning and sequencing, using nested and speci®c (VECN, Genosys and P16) primers.
Sequence analysis
Preliminary analysis of the LPHH1 mRNA sequence revealed that two discrete regions, one on each side of the transmembrane encoding domain, were alternatively spliced. This observation was veri®ed across a panel of cDNAs from a range of tumour and normal samples (Figure 1) . Furthermore, PCR analysis of the variable regions in a panel of aliquots of cDNA libraries, derived from a range of normal tissues, suggested some measures of bias in isoform expression depending on tissue source (data not shown). The situation in the human may be even more complicated. RT-PCR analysis of the variable regions in total cDNA (Figure 1) shows a slightly dierent spectrum of products (particularly in the 5' domain in the normal breast sample) to that seen in the analysis of the variants present in full coding sequence ampli®cations. One possible explanation is that alternative splicing occurs additionally in areas outside the two variable domains such that by priming for full-length cDNA, we are looking to some extent at a sub-fraction of LPHH1 mRNA molecules. Long-range PCR and sequencing of genomic DNA from BAC 61G4 con®rmed that the transcript variability was generated by alternative splicing events. Ampli®cation of 5' and 3' regions of the cDNA from a 61G4 target suggested that the majority, if not all of the gene, was encoded from within the BAC insert. Table 1 The oligonucleotide primers used in this study are detailed. In one case (P37) a mixed synthesis at one position was used, as the primary sequence was not fully clear at the time Primer Lab Desig. Sequence   P1  P2  P3  P4  P5  P6  P7  P8  P9  P10  P11  P12  P13  P14  P15  P16  P17  P18  P19  P20  P21  P22  P23  P24  P25  P26  P27  P28  P29  P30  P31  P32  P33  P34  P35  P36  P37  P38  P39  P40  P41   BEGIN  INTER  30F  30R  50F  50R  170R  170F  250R  250F  300F  300R  C4-2R  C4-2F  JVECN  7EXT  7R  7GO  7R-1  7R-2  AS2  7-6  7-5  TMI  7-3  AS3  7-2  AS4  7F  2rev2  2rev3  AS5  7C  AS6  AF  AR  3 1402 residue product 1173 residue truncated product with altered C-terminus 1163 residue truncated product with altered C-terminus 1445 residue product (in frame insertion) 1415 residue product (in frame insertion) 1186 residue truncated product with altered C-terminus 1176 residue truncated product with altered C-terminus 1177 residue truncated product with altered C-terminus 1458 residue product (twin in frame insertions)
In addition to a numerical estimate, the ®nal column describes the predicted eect of the variant sequence on the gene product. A and B refer to alternatives in the N-terminal domain, while V ± Z represent alternatives of the C-terminal variable region. It should be noted that, as determined by direct sequence analysis of RT ± PCR ampli®ed full length products, the majority of the coding regions of the variant mRNAs are identical. Chi squared analysis was carried out using SPSS
The full-length cDNA products were ampli®ed and the major mRNA species from the normal breast (Table 2 , form AV) and the corresponding cDNA from MDA231 were identi®ed, cloned and sequenced in a combination of direct (majority of ORF) and cloned based (variable domains) analysis. This strategy allowed exclusion of PCR/cloning artifacts in the ®nal sequence, which showed a 4209 bp open reading frame (Figure 2 ) with 65% homology to the published rat cDNA sequences (Accession Nos. U78105, U72487). The analysis also showed sequence identity in directly comparable cDNAs, from the normal tissue and tumour line. The encoded peptide showed 66% amino acid identity with rat latrophilin over 1402 residues. As predicted for the rat protein, the human sequence appeared to have a cleavable N-terminal signal sequence (although the primary structures of both showed little homology), seven transmembrane domains and multiple potential glycosylation sites. The N-terminus was predicted to be extracellular with the C-terminus cytoplasmic. The human protein contained one potential PEST sequence (residues 1322 ± 1340) against three such predicted regions in the C-terminus of the rat peptide. In order to characterize the relative abundance and nature of the two alternatively spliced domains, sited either side of the transmembrane region, individual cDNA clones from the normal breast (31) and MDA231 (27) were analysed. A clear dierence was apparent, in that the transcripts from the normal tissue were much more homogenous (P50.001) than those derived from the tumour cell line ( Table 2 ). The eect of the alternative splice events was variable, with some exons (Figure 3 ) introducing additional amino acids (to produce a sequence more closely related to the described rat product in variant B) while others encoded an altered and truncated carboxy-terminal (cytoplasmic) domain. The latter class of gene product (forms AW, BW) was the most highly represented in the tumour line.
Expression analysis in tumour lines and normal tissue
Hybridization of an LPHH1 probe against mRNAs derived from a wide range of adult and foetal tissues con®rmed widespread expression, with all tissues showing some degree of signal (Figure 4) . The mRNA loading on the blot used is normalized with eight housekeeping genes, and therefore provides a semi-quantitative assessment of relative expression levels in the dierent tissues. High levels of expression appeared to occur in, among other tissues, foetal and adult lung. Our original interest in LPHH1 arose from the observation that it lay within a region of the genome that appeared to be perturbed in human malignancy. We therefore analysed gene expression in a panel of human tumour cell lines. Probes to the 3' and 5' end of the gene were used and both showed a similar hybridization pattern ( Figure 5 ). In two cell lines, MDA231 and SK-N-SH (neuroblastoma) expression appeared to be at a relatively high level whereas in others such as SK-UT-1B (leiomyosarcoma) and KARPAS-620 (multiple myeloma) it seemed respectively to be low or completely absent. The KARPAS-620 result was con®rmed by standard ( Figure 1 ) and multiplex ( Figure 5 ) RT-PCR, both Figure 3 In order to determine the sequence of the variable domains, PCR products derived from individual cDNA molecules were analysed, following cloning. Products were cloned using a TOPO XL PCR Cloning TM Kit (Invitrogen). Brie¯y, the fragment (0.5 mg) was excised from a crystal violet containing, agarose gel and ligated, in a 5 min reaction, into the positive selection plasmid vector. Following transformation of the host strain, individual colonies were analysed by PCR to con®rm fragment insertion. When cloning full length cDNA (*5 kb) products, two consecutive rounds of gel puri®cation of the target fragments were carried out. This markedly increased the cloning eciency of the large fragments. Where possible, the variable domains from multiple clones from both sources were sequenced and compared in order to exclude PCR derived artifacts. LPHH1 transcripts were placed into 9 classes ( Table 2 ). The sequences of the variable regions, compared to the product in Figure 2 , are shown. The upper-case sequence represents this major mRNA, the lowercase represents the alternative sequence. Variant B re¯ects an insertion into the 5' domain after nucleotide 1962. Variants W ± Z re¯ect insertions into the 3' domain after nucleotide 3638. Two of the variants (W and X) show base and predicted amino acid identity over part of their sequence. The block marked TM7 in the line diagram represents the transmembrane domain The marked dierences in gene expression between the two species might suggest that the human gene is not a simple functional homologue of the rat sequence. A relative lack of homology in the putative eector binding, C-terminal region is consistent with this hypothesis. Additionally, the high level of splice generated variability, seen in the human mRNA products from normal tissue, has not been reported in the rat. However, a comparison of the two independently derived sequences in Genbank shows a slight dierence, with the single amino-acid isoleucine at position 132 in one being replaced by the six amino-acids KVEQKV in the other (Krasnoperov et al., 1997; Lelianova et al., 1997) . It is possible that this represents an alternative splice event. The biological signi®cance of such variability is unknown, although it is tempting to speculate that it may re¯ect specialized ligand/eector binding and hence function. Complex alternative splicing has been reported for other cell surface glycoproteins, such as CD44, where expression of particular variants has been correlated with a metastatic phenotype (Yamamichi et al., 1998) . Again highly speculative, is our suggestion that dierent normal tissues may preferentially express speci®c forms. This observation is based on the ampli®cation of speci®c variable domain fragments from cDNA libraries derived from individual tissues. The possibility remains that this is a consequence of library construction protocols. Therefore, systematic con®rmations of such preliminary observations are critical before hypotheses are formed.
The C-terminus of the rat peptide is rich in proline residues, which contributes to the prediction of three internal PEST regions. Such sequences are thought to contribute to the rapid turnover of proteins (Rechsteiner and Rogers, 1996) . In contrast, the human peptide is not proline rich, although it still has one predicted PEST domain. The presence of such sequences in both molecules suggests that the encoded proteins might be relatively unstable. It is notable that the major products in the tumour line (AW,BW) would be predicted to lack a PEST region and may consequently show increased stability.
The dierence in level of transcript variability observed between the tumour line and the normal tissue may simply re¯ect a loss of control of splice ®delity in the tumour. However, at this time, we are unable to dismiss the hypothesis that the altered expression pattern contributes in some way to malignancy. Similarly, the Northern data from tumour cell lines would suggest that expression is highly variable with some lines failing to express the transcript completely while others appear to express it at relatively high levels, an observation somewhat at odds with the expression seen in normal tissues. We feel that this analysis, coupled with data which indicates that the area surrounding and including the 1p31.1 SRO is very gene poor, suggests that the potential role of LPHH1 in malignant disease should be considered further.
